Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Clinical characteristics and risk factors of non-Candida fungaemia

Authors: Masaki Yamamoto, Shunji Takakura, Gou Hotta, Yasufumi Matsumura, Aki Matsushima, Miki Nagao, Yutaka Ito, Satoshi Ichiyama

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

The incidence of fungaemia has been increasing worldwide. It is important to distinguish non-Candida fungaemia from candidaemia because of their different antifungal susceptibilities. The aims of this study were to investigate the clinical characteristics of non-Candida fungaemia and identify the clinical factors that differentiate it from candidaemia.

Methods

We investigated the clinical manifestations and mortality of non-Candida fungaemia in Kyoto University Hospital from 2004 to 2009.

Results

There were 110 episodes of fungaemia during the study period. There were 11 renal replacement therapy episodes of fungaemia due to non-Candida yeasts (10.0%), including 6 episodes with Cryptococcus neoformans, 4 with Trichosporon asahii, and 1 with Kodamaea ohmeri, in addition to 99 episodes of candidaemia (90.0%). The presence of collagen disease [odds ratio (OR) 9.00; 95% confidence interval (CI) 1.58-51.4; P = 0.01] or renal replacement therapy (OR 15.0; 95% CI 3.06-73.4; P < 0.01) was significantly more common in non-Candida fungaemia patients than in candidaemia patients. Prior colonisation by the species may be a predictor of non-Candida fungaemia. Non-Candida fungaemia had a higher mortality than candidaemia (54.5% versus 21.2%, P = 0.03).

Conclusions

Although Candida species frequently cause fungaemia, we should also be aware of non-Candida yeasts because of their high mortality, particularly among high-risk patients, such as those with collagen disease and those under renal replacement therapy. Prior colonisation by the causative organisms may be an important predictor of non-Candida fungaemia.
Literature
1.
2.
go back to reference Anunnatsiri S, Chetchotisakd P, Mootsikapun P: Fungemia in non-HIV-infected patients: a five-year review. Int J Infect Dis. 2009, 13 (1): 90-96. 10.1016/j.ijid.2008.04.009.CrossRefPubMed Anunnatsiri S, Chetchotisakd P, Mootsikapun P: Fungemia in non-HIV-infected patients: a five-year review. Int J Infect Dis. 2009, 13 (1): 90-96. 10.1016/j.ijid.2008.04.009.CrossRefPubMed
3.
go back to reference Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP: Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012, 64 (1): 68-75. 10.1016/j.jinf.2011.11.002.CrossRefPubMed Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP: Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012, 64 (1): 68-75. 10.1016/j.jinf.2011.11.002.CrossRefPubMed
4.
go back to reference Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, Raad II: Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis. 2004, 36 (8): 564-569. 10.1080/00365540410017563.CrossRefPubMed Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, Raad II: Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis. 2004, 36 (8): 564-569. 10.1080/00365540410017563.CrossRefPubMed
5.
go back to reference Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, Rincon C, Hortal J, Pelaez T: Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005, 40 (11): 1625-1634. 10.1086/429916.CrossRefPubMed Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, Rincon C, Hortal J, Pelaez T: Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005, 40 (11): 1625-1634. 10.1086/429916.CrossRefPubMed
6.
go back to reference Riedel DJ, Johnson JK, Forrest GN: Rhodotorula glutinis fungemia in a liver-kidney transplant patient. Transpl Infect Dis. 2008, 10 (3): 197-200. 10.1111/j.1399-3062.2007.00265.x.CrossRefPubMed Riedel DJ, Johnson JK, Forrest GN: Rhodotorula glutinis fungemia in a liver-kidney transplant patient. Transpl Infect Dis. 2008, 10 (3): 197-200. 10.1111/j.1399-3062.2007.00265.x.CrossRefPubMed
7.
go back to reference Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC: Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis. 2003, 22 (4): 254-257.PubMed Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC: Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis. 2003, 22 (4): 254-257.PubMed
8.
go back to reference Goldani LZ, Mario PS: Candida tropicalis fungemia in a tertiary care hospital. J Infect. 2003, 46 (3): 155-160. 10.1053/jinf.2002.1067.CrossRefPubMed Goldani LZ, Mario PS: Candida tropicalis fungemia in a tertiary care hospital. J Infect. 2003, 46 (3): 155-160. 10.1053/jinf.2002.1067.CrossRefPubMed
9.
10.
go back to reference Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL, Gobernado M: Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002, 21 (11): 767-774. 10.1007/s10096-002-0822-1.CrossRefPubMed Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL, Gobernado M: Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002, 21 (11): 767-774. 10.1007/s10096-002-0822-1.CrossRefPubMed
11.
go back to reference Miceli MH, Diaz JA, Lee SA: Emerging opportunistic yeast infections. Lancet Infect Dis. 2011, 11 (2): 142-151. 10.1016/S1473-3099(10)70218-8.CrossRefPubMed Miceli MH, Diaz JA, Lee SA: Emerging opportunistic yeast infections. Lancet Infect Dis. 2011, 11 (2): 142-151. 10.1016/S1473-3099(10)70218-8.CrossRefPubMed
12.
go back to reference National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A2. 2002, Villanova, PA, USA: NCCLS National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A2. 2002, Villanova, PA, USA: NCCLS
13.
go back to reference Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010, 50 (3): 291-322. 10.1086/649858.CrossRefPubMed Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010, 50 (3): 291-322. 10.1086/649858.CrossRefPubMed
14.
go back to reference Charles PE, Dalle F, Aube H, Doise JM, Quenot JP, Aho LS, Chavanet P, Blettery B: Candida spp. Colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 2005, 31 (3): 393-400. 10.1007/s00134-005-2571-y.CrossRefPubMed Charles PE, Dalle F, Aube H, Doise JM, Quenot JP, Aho LS, Chavanet P, Blettery B: Candida spp. Colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 2005, 31 (3): 393-400. 10.1007/s00134-005-2571-y.CrossRefPubMed
15.
go back to reference Takakura S, Fujihara N, Saito T, Kimoto T, Ito Y, Iinuma Y, Ichiyama S: Improved clinical outcome of patients with Candida bloodstream infections through direct consultation by infectious diseases physicians in a Japanese university hospital. Infect Control Hosp Epidemiol. 2006, 27 (9): 964-968. 10.1086/504934.CrossRefPubMed Takakura S, Fujihara N, Saito T, Kimoto T, Ito Y, Iinuma Y, Ichiyama S: Improved clinical outcome of patients with Candida bloodstream infections through direct consultation by infectious diseases physicians in a Japanese university hospital. Infect Control Hosp Epidemiol. 2006, 27 (9): 964-968. 10.1086/504934.CrossRefPubMed
16.
go back to reference Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006, 43 (1): 25-31. 10.1086/504810.CrossRefPubMed Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006, 43 (1): 25-31. 10.1086/504810.CrossRefPubMed
17.
go back to reference Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A: Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses. 2002, 45 (5–6): 141-145.CrossRefPubMed Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A: Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses. 2002, 45 (5–6): 141-145.CrossRefPubMed
18.
go back to reference Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005, 49 (9): 3640-3645. 10.1128/AAC.49.9.3640-3645.2005.CrossRefPubMedPubMedCentral Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005, 49 (9): 3640-3645. 10.1128/AAC.49.9.3640-3645.2005.CrossRefPubMedPubMedCentral
19.
go back to reference Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, Torres-Rodriguez JM: Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study group of fungal infection in the ICU. Intensive Care Med. 1997, 23 (1): 23-30. 10.1007/s001340050286.CrossRefPubMed Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, Torres-Rodriguez JM: Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study group of fungal infection in the ICU. Intensive Care Med. 1997, 23 (1): 23-30. 10.1007/s001340050286.CrossRefPubMed
Metadata
Title
Clinical characteristics and risk factors of non-Candida fungaemia
Authors
Masaki Yamamoto
Shunji Takakura
Gou Hotta
Yasufumi Matsumura
Aki Matsushima
Miki Nagao
Yutaka Ito
Satoshi Ichiyama
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-247

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine